Currently, there is no standard therapy that is uniformly effective in treating anemia of malignancy or bone marrow failure.Anemia in these patients isgenerally managed w/transfusion of blood products. However, there are several risks asso-ciated w/transfusions including frebrile reactions, alloimmunization, and transmission of bloodborn infections. Recombinant EPO is effective in fraction of patients generally in those in whom endogenous EPO levels are not very high.
Showing the most recent 10 out of 1085 publications